NexImmune Inc (NEXI)

[StockLogistics]

Soon I think “4:19p ET 8/15/2022 - Benzinga
NexImmune Highlights FDA Clearance Of IND For NEXI-003 For The Treatment Of HPV-Related Cancers

Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company's first solid tumor product candidate for the treatment of HPV-related cancers
Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22
Clinical updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 4Q22
Company is prioritizing resources to support Company's lead product candidates, NEXI-001 and NEXI-003
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”